S-adenosyl-L-methionine modulates firing rate of dorsal motor nucleus of the vagus neurones in vitro.
We used the patch clamp technique applied to an in vitro brain slice preparation to examine the changes in firing activity of single dorsal vagal motoneurones exposed to S-adenosyl-methionine. In approximately 70% of the neurones tested, S-adenosyl-L-methionine (1-100 microM) decreased the spontaneously occurring firing in a dose dependent manner; the plateau decrease was 40 +/- 6%. The peak effect was observed approximately 5 min after the superfusion with S-adenosyl-L-methionine was started, and was usually reversible upon wash out of S-adenosyl-L-methionine from the superfusing chamber. No effect of the control salt of S-adenosyl-L-methionine, 1,4-butane-disulfonate.NA (100 microM), was observed. The frequency of discharge observed upon depolarization steps from hyperpolarized potentials was reduced to 34 +/- 17% (n = 11) of control upon S-adenosyl-L-methionine (100 microM) superfusion; no effect of S-adenosyl-L-methionine was observed on the action potential threshold. Preincubation with adenosine receptor antagonists, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, 10 nM) and 3,7-dimethyl-1-propargylxanthine (DMPX, 50 microM), reversed the S-adenosyl-L-methionine-induced inhibition of firing rate, and in fact, in the presence of these adenosine antagonists, S-adenosyl-L-methionine increased the firing rate of vagal motoneurones. This excitation of vagal motoneurones was blocked by pretreatment with S-adenosyl-homocysteine (100 microM), an inhibitor of methylation reactions. It is concluded that the inhibitory activity of S-adenosyl-L-methionine on the firing rate of vagal motoneurones is due to its metabolic transformation into adenosine which then acts on adenosine receptors. The excitatory effect on firing rate appears to be due to other actions, possibly including methylation reactions of key components of signal transduction mechanisms.
Travagli
R A
RA
Department of Pharmacology, Georgetown University, School of Medicine, Washington, DC 20007.
Gillis
R A
RA
Kellar
K J
KJ
D000200:Action Potentials / Q000187:drug effects; D000476:Alkanesulfonates / Q000494:pharmacology; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004594:Electrophysiology; D005260:Female; D008297:Male; D008745:Methylation; D009046:Motor Neurons / Q000187:drug effects* / Q000502:physiology; D018408:Patch-Clamp Techniques; D058915:Purinergic P1 Receptor Antagonists; D051381:Rats; D017207:Rats, Sprague-Dawley; D012435:S-Adenosylhomocysteine / Q000494:pharmacology; D012436:S-Adenosylmethionine / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects; D013805:Theobromine / Q000031:analogs & derivatives / Q000494:pharmacology; D014630:Vagus Nerve / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D014970:Xanthines / Q000494:pharmacology
D000476:Alkanesulfonates; D058915:Purinergic P1 Receptor Antagonists; D014970:Xanthines; C092739:1,4-butanedisulfonate; C057837:3,7-dimethyl-1-propargylxanthine; D012436:S-Adenosylmethionine; D012435:S-Adenosylhomocysteine; C051360:1,3-dipropyl-8-cyclopentylxanthine; D013805:Theobromine